Progressive Neurodegeneration in the Chronic MPTP/Probenecid Model of Parkinson’s Disease

Parkinson's Disease

Volumn , Issue , 2004, Pages 109-115

  Lau, Yuen Sum ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85160143089     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203508596-21     Document Type: Chapter

References (55)

1. Fahn, S., Description of Parkinson’s disease as a clinical syndrome, Ann. N. Y. Acad. Sci., 991, 1, 2003.
2. Braak, H. et al., Pattern of brain destruction in Parkinson’s and Alzheimer’s diseases, J. Neural Transm, 103, 455, 1996.
3. Forno, L. S., Neuropathology of Parkinson’s disease, J. Neuropathol. Exp. Neurol., 55, 259, 1996.
4. Kuzuhara, S. et al., Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study, Acta Neuropathol. (Berl.), 75, 345, 1988.
5. Bancher, C. et al., An antigenic profile of Lewy bodies: Immunocytochemical indication for protein phosphorylation and ubiquitination, J. Neuropathol. Exp. Neurol., 48, 81, 1989.
6. Spillantini, M. G. et al., Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci. USA, 95, 6469, 1998.
7. Gai, W. P. et al., In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies, Exp. Neurol., 166, 324, 2000.
8. Shimura, H. et al., Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson’s disease, Science, 293, 263, 2001.
9. Tatton, N. A. et al., A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson’s disease, Ann. Neurol., 44, S142, 1998.
10. Hartmann, A. et al., Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease, Proc. Natl. Acad. Sci. USA, 97, 2875, 2000.
11. Tatton, N. A., Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease, Exp. Neurol., 166, 29, 2000.
12. Ungerstedt, U., 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: The turning syndrome, Pharmacol. Ther., 2, 37, 1976.
13. Schwarting, R. K. and Huston, J. P., The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments, Prog. Neurobiol., 50, 275, 1996.
14. Montastruc, J. L. et al., Drug-induced parkinsonism: A review, Fundam. Clin. Pharmacol. 8, 293, 1994.
15. Ferrante, R. J. et al., Systemic administration of rotenone produces selective damage in the striatum and glo114 Parkinson’s Disease bus pallidus, but not in the substantia nigra, Brain Res., 753, 157, 1997.
16. Betarbet, R., et al., Chronic systemic pesticide exposure reproduces features of Parkinson’s disease, Nat. Neurosci., 3, 1301, 2000.
17. Corasaniti, M. T. et al., Paraquat: A useful tool for the in vivo study of mechanisms of neuronal cell death, Pharmacol. Toxicol., 83, 1, 1998.
18. Thiruchelvam, M., et al., The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: Implications for Parkinson’s disease, J. Neurosci., 20, 9207, 2000.
19. Feany, M. B. and Bender, W. W., A Drosophila model of Parkinson’s disease, Nature, 404, 394, 2000.
20. Masliah, E. et al., Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders, Science, 287, 1265, 2000.
21. Gao, H. M. et al., Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson’s disease, J. Neurochem., 81, 1285, 2002.
22. Lau, Y. S. and Meredith, G. E., From drugs of abuse to parkinsonism. The MPTP mouse model of Parkinson’s disease, Methods Mol. Med., 79, 103, 2003.
23. Ballard, P. A., Tetrud, J. W., and Langston, J. W., Permanent human parkinsonism due to 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP): Seven cases, Neurology, 35, 949, 1985.
24. Burns, R. S. et al., The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), N. Engl. J. Med., 312, 1418, 1985.
25. Burns, R. S. et al., A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Proc. Natl. Acad. Sci. USA, 80, 4546, 1983.
26. Gerlach, M. and Riederer, P., Animal models of Parkinson’s disease: An empirical comparison with the phenomenology of the disease in man, J. Neural Transm., 103, 987, 1996.
27. Eidelberg, E. et al., Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys, Neuroscience, 18, 817, 1986.
28. Langston, J. W. et al., Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure, Ann. Neurol., 46, 598, 1999.
29. Forno, L. S. et al., Similarities and differences between MPTP-induced parkinsonsim and Parkinson’s disease. Neuropathologic considerations, Adv. Neurol. 60, 600, 1993.
30. Kowall, N. W. et al., MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons, Neuroreport, 11, 211, 2000.
31. Singer, T. P. et al., Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, J. Neurochem., 49, 1, 1987.
32. Gainetdinov, R. R. et al., Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter, J. Neurochem., 69, 1322, 1997.
33. Leist, M. et al., 1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis, Mol. Pharmacol., 54, 789, 1998.
34. Cleeter, M. W., Cooper, J. M., and Schapira, A. H., Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement, J. Neurochem., 58, 786, 1992.
35. Chan, P. et al., Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain, J. Neurochem., 57, 348, 1991.
36. Jenner, P., Oxidative mechanisms in nigral cell death in Parkinson’s disease, Mov. Disord., 13, 24, 1998
37. Souza, J. M., et al., Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies, J. Biol. Chem., 275, 18344, 2000.
38. Tatton, N. A. and Kish, S. J., In situ detection of apoptotic nuclei in the substantia nigra compacta of 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labeling and acridine orange staining, Neuroscience, 77, 1037, 1997.
39. Kay, J. N. and Blum, M., Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection, Dev. Neurosci., 22, 56, 2000.
40. Mao, L. et al., Profound astrogenesis in the striatum of adult mice following nigrostriatal dopaminergic lesion by repeated MPTP administration, Brain Res. Dev. Brain Res., 131, 57, 2001.
41. Schneider, J. S. and Roeltgen, D. P., Delayed matchingto-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys, Brain Res., 615, 351, 1993.
42. Bezard, E. et al., A chronic MPTP model reproducing the slow evolution of Parkinson’s disease: Evolution of motor symptoms in the monkey, Brain Res., 766, 107, 1997.
43. Lau, Y.-S. et al., Effects of probenecid on striatal dopamine depletion in acute and long-term1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, Gen. Pharmacol., 21, 181, 1990.
44. Petroske, E. et al., Mouse model of parkinsonism: A comparison between subacute MPTP and chronic MPTP/probenecid treatment, Neuroscience, 106, 589, 2001.
45. Meredith, G. E. et al., Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson’s disease, Brain Res., 956, 156, 2002.
46. Langston, J. W. et al., Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219, 979, 1983.
47. Langston, J. W. and Ballard, P. A. Jr., Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, N. Engl. J. Med., 309, 310, 1983.
48. Yang, S. C. et al., Recommended safe practices for using the neurotoxin MPTP in animal experiments, Lab. Anim. Sci., 38, 563, 1988.
49. Przedborski, S. et al., The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety, J. Neurochem., 76, 1265, 2001.
50. Crampton, J. M. et al., MPTP in mice: treatment, distribution and possible source of contamination, Life Sci., 42, 73, 1988.
51. Lau, Y. S., Crampton, J. M., and Wilson, J. A., Urinary excretion of MPTP and its primary metabolites in mice, Life Sci., 43, 1459, 1988.
52. Giovanni, A., Sonsalla, P. K., and Heikkila, R. E., Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium, J. Pharmacol. Exp. Ther., 270, 1008, 1994.
53. Lau, Y. S. et al., Depletion of striatal dopamine by the N-oxide of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Neurotoxicology, 12, 189, 1991.
54. Johannessen, J. N. et al., 1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent, Life Sci., 38, 743, 1986.
55. Chiba, K. et al., Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice, J. Pharmacol. Exp. Ther., 246, 1108, 1988